A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection
- Conditions
- COVID-19
- Interventions
- Biological: COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injectionBiological: COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injectionBiological: COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participantsBiological: COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participantsBiological: COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participantsBiological: COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants
- Registration Number
- NCT05047445
- Lead Sponsor
- Scancell Ltd
- Brief Summary
The main objectives of this study are to assess the safety, tolerability and immunogenicity of the candidate SARS-CoV-2 vaccine, COVIDITY, when administered using a needle-free ID or IM injection device.
- Detailed Description
This is a first time in human (FTiH) study designed to explore the safety, tolerability, and immunogenicity of COVIDITY in healthy adults when administered by needle-free injection.
COVIDITY consists of two DNA plasmid vaccines (SCOV1 and SCOV2). SCOV1 is expected to be active against the original SARS-CoV-2 strain and the B.1.1.7 (Alpha) variant, and to a slightly lesser extent against the B.1.351 (Beta) and P.1 (Gamma) variants. SCOV2 is expected to boost the effects of SCOV1 while providing further enhanced protection against the B.1.351 (Beta) and P.1 (Gamma) variants. Antibodies induced by SCOV1 and SCOV2 also show strong binding to the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants in nonclinical models.
When the study commenced in 2021 there were significant numbers of unvaccinated individuals who also had no known exposure to SARS-CoV-2; however as the epidemiology rapidly changed with most people having either been vaccinated, or infected with SARS-CoV-2, or both, the use of SCOV2 only in these populations made rational sense, particularly as it has more mutations in common with the Omicron variant. A protocol amendment submitted in February 2022, permitted the enrolment of participants irrespective of their previous COVID-19 vaccination and/or SARS-CoV-2 infection status, amended the treatment regimen to SCOV2 only, and aligned the administered dose with the doses employed for other DNA vaccines. Immunogenicity analyses will be performed separately for the vaccine-naïve, previously vaccinated and previously infected immunogenicity analysis populations.
Eligible participants will be randomised 1:1 to be vaccinated by either IM or ID needle-free injection in blocks determined by their previous COVID-19 vaccination and SARS-CoV-2 infection status, as follows:
Participants enrolled under the initial protocol (Amendment 1): Two doses of SCOV1 (administered on Day 1 and Day 29), followed by two doses of SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]). A final end of study assessment will then be performed 6 weeks after last dose of study vaccine (Day 183).
Participants enrolled under protocol Amendment 2: Vaccine Naive and Previously Vaccinated participants: Two doses of SCOV2 (administered on Day 1 and Day 29) with a final end of study assessment performed 6 weeks after last dose of study vaccine (Day 71); Previously Infected participants: A single dose of SCOV2 (administered on Day 1) with a final end of study assessment performed 6 weeks after last dose of study vaccine (Day 43)
Each dose of SCOV1 and/or SCOV2 will be administered via needle-free injection, either intradermally (study Arm 1; PharmaJet Tropis® device) or intramuscularly (study Arm 2; PharmaJet Stratis® device). Eligible injection sites include the outer aspect of the upper left or right arm (medial deltoid muscle) or the left or right outer thigh (lateralis muscle).
This study is expected to enrol up to 80 participants at a single centre in South Africa. Enrolment will attempt to continue until at least 10 evaluable participants receive all protocol-required SCOV2 vaccinations for each immunogenicity analysis population. However, should the epidemiology be such that certain populations cannot be enrolled, the Safety Review Committee may determine that enrolment for that population be considered complete.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 80
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description COVIDITY administered via needle-free intradermal injection (PharmaJet Tropis) COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participants - COVIDITY administered via needle-free intradermal injection (PharmaJet Tropis) COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants - COVIDITY administered via needle-free intramuscular injection (PharmaJet Stratis) COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants - COVIDITY administered via needle-free intradermal injection (PharmaJet Tropis) COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection - COVIDITY administered via needle-free intramuscular injection (PharmaJet Stratis) COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participants - COVIDITY administered via needle-free intramuscular injection (PharmaJet Stratis) COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection -
- Primary Outcome Measures
Name Time Method Safety and tolerability of COVIDITY as assessed by the recording of adverse events (AEs) From enrolment through end of study; approximately 6 to 26 weeks National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events; CTCAE v5.0.
Safety and tolerability of COVIDITY as assessed by a physical examination of the participant From enrolment through end of study; approximately 6 to 26 weeks Physical examination findings (binary classification: normal or abnormal)
Safety and tolerability of COVIDITY as assessed by serum chemistry From enrolment through end of study; approximately 6 to 26 weeks Total protein (g/L)
Safety and tolerability of COVIDITY as assessed by local and systemic reactogenicity events From enrolment through end of study; approximately 6 to 26 weeks Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (US FDA 2007).
Local reactogenicity events will be measured for the injection site using a 4-point scale where 1 = 'mild' and 4 = 'potentially life-threatening'.
Systemic reactogenicity events of interest include fever, chills, headache, myalgia, arthralgia, fatigue, nausea, vomiting, diarrhoea, rhinorrhoea, wheezing, general feeling of being unwell, and loss of appetite.Safety and tolerability of COVIDITY as assessed by the onset of any new chronic medical conditions From enrolment through end of study; approximately 6 to 26 weeks Safety and tolerability of COVIDITY as assessed by the recording of vital signs From enrolment through end of study; approximately 6 to 26 weeks Systolic and diastolic blood pressure (mm Hg)
Safety and tolerability of COVIDITY as assessed by haematology From enrolment through end of study; approximately 6 to 26 weeks White blood cell differential (cells x 10\^9/L)
Safety and tolerability of COVIDITY as assessed by coagulation parameters and biomarkers From enrolment through end of study; approximately 6 to 26 weeks D-dimer (ng/mL)
Safety and tolerability of COVIDITY as assessed by urinalysis From enrolment through end of study; approximately 6 to 26 weeks Microscopy (if clinically indicated only) examination for bacteria, red blood cells, white blood cells, casts, and crystals (binary classification: absent or present)
Safety and tolerability of COVIDITY as assessed by 12-lead electrocardiogram (ECG) From enrolment through end of study; approximately 6 to 26 weeks Heart rate, PR-interval, QRS-duration, QT-interval, corrected QT-interval by Fridericia (QTcF), general morphology, and the interpretation of the ECG by the Investigator
- Secondary Outcome Measures
Name Time Method The immunogenicity of COVIDITY as assessed by antibody response From enrolment through end of study; approximately 6 to 26 weeks Quantitative COVIDITY-specific antibody responses measured by enzyme-linked immunosorbent assay (ELISA) or using the Meso Scale Discovery (MSD) platform
The immunogenicity of COVIDITY as assessed by seroconversion and/or increase in antibody titre From enrolment through end of study; approximately 6 to 26 weeks The proportion of participants who seroconvert and/or have a 4-fold increase in N ± S protein antibody titre from baseline
The immunogenicity of COVIDITY as assessed by T cell response From enrolment through end of study; approximately 6 to 26 weeks Quantitative COVIDITY-specific T cell responses measured by ELISpot assay
Trial Locations
- Locations (1)
University of Cape Town Lung Institute, Centre for TB Research Innovation
🇿🇦Cape Town, Western Cape, South Africa